Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.

Pilotto A, Franceschi M, D'Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L, Paris F, Matera MG, Pilotto A, Daniele A, Mecocci P, Masullo C, Dallapiccola B, Seripa D.

Neurology. 2009 Sep 8;73(10):761-7. doi: 10.1212/WNL.0b013e3181b6bbe3.

2.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
3.

Pharmacogenomics in Alzheimer's disease.

Cacabelos R.

Methods Mol Biol. 2008;448:213-357. doi: 10.1007/978-1-59745-205-2_10. Review.

PMID:
18370236
4.

Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Xiao T, Jiao B, Zhang W, Tang B, Shen L.

CNS Drugs. 2016 Oct;30(10):899-907. doi: 10.1007/s40263-016-0356-1. Review.

PMID:
27282366
5.

Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.

Cacabelos R, Llovo R, Fraile C, Fernández-Novoa L.

Curr Alzheimer Res. 2007 Sep;4(4):479-500. Review.

PMID:
17908053
6.

Pharmacogenomics and therapeutic prospects in dementia.

Cacabelos R.

Eur Arch Psychiatry Clin Neurosci. 2008 Mar;258 Suppl 1:28-47. doi: 10.1007/s00406-007-1006-x. Review.

PMID:
18344047
7.
8.

The application of functional genomics to Alzheimer's disease.

Cacabelos R.

Pharmacogenomics. 2003 Sep;4(5):597-621. Review.

PMID:
12943467
9.

Cytochrome P450 2D6.

Owen RP, Sangkuhl K, Klein TE, Altman RB.

Pharmacogenet Genomics. 2009 Jul;19(7):559-62. doi: 10.1097/FPC.0b013e32832e0e97. Review. No abstract available.

Supplemental Content

Support Center